Acumen Pharmaceuticals IncNASDAQ:ABOS
- LAST PRICE3.1900
- TODAY'S CHANGE (%)0.0100 (0.3145%)
- Bid / Lots3.1000/ 2
- Ask / Lots3.2300/ 10
- Open / Previous Close3.1100 / 3.1800
- Day Range
- 52 Week Range
- Volume167,647
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ABOS |
|---|---|---|
| 09:32 ET | 4308 | 3.14 |
| 09:36 ET | 2181 | 3.13 |
| 09:38 ET | 200 | 3.11 |
| 09:39 ET | 369 | 3.1 |
| 09:41 ET | 2490 | 3.09 |
| 09:43 ET | 1700 | 3.11 |
| 09:48 ET | 837 | 3.11 |
| 09:50 ET | 1799 | 3.095 |
| 09:52 ET | 500 | 3.1 |
| 09:54 ET | 1000 | 3.1 |
| 09:57 ET | 2200 | 3.09 |
| 09:59 ET | 500 | 3.0999 |
| 10:01 ET | 100 | 3.0979 |
| 10:03 ET | 1000 | 3.08 |
| 10:06 ET | 100 | 3.08 |
| 10:08 ET | 200 | 3.08 |
| 10:14 ET | 615 | 3.09 |
| 10:15 ET | 430 | 3.085 |
| 10:17 ET | 1800 | 3.09 |
| 10:30 ET | 500 | 3.1 |
| 10:32 ET | 10101 | 3.1 |
| 10:33 ET | 500 | 3.0999 |
| 10:35 ET | 1025 | 3.0949 |
| 10:37 ET | 200 | 3.09 |
| 10:42 ET | 1092 | 3.09 |
| 10:46 ET | 100 | 3.07 |
| 10:48 ET | 150 | 3.07 |
| 10:57 ET | 113 | 3.0799 |
| 11:00 ET | 700 | 3.08 |
| 11:04 ET | 100 | 3.09 |
| 11:06 ET | 100 | 3.095 |
| 11:15 ET | 277 | 3.1 |
| 11:24 ET | 500 | 3.1001 |
| 11:27 ET | 100 | 3.1 |
| 11:36 ET | 500 | 3.077 |
| 11:45 ET | 100 | 3.07 |
| 11:49 ET | 131 | 3.07 |
| 11:51 ET | 100 | 3.07 |
| 11:54 ET | 600 | 3.0709 |
| 11:56 ET | 400 | 3.08 |
| 12:00 ET | 100 | 3.09 |
| 12:02 ET | 200 | 3.105 |
| 12:03 ET | 10681 | 3.08 |
| 12:05 ET | 300 | 3.09 |
| 12:07 ET | 100 | 3.1 |
| 12:18 ET | 100 | 3.09 |
| 12:21 ET | 468 | 3.0998 |
| 12:23 ET | 200 | 3.09 |
| 12:25 ET | 11321 | 3.1 |
| 12:38 ET | 300 | 3.1 |
| 12:39 ET | 830 | 3.11 |
| 12:45 ET | 100 | 3.12 |
| 01:01 ET | 170 | 3.125 |
| 01:03 ET | 100 | 3.125 |
| 01:06 ET | 522 | 3.14 |
| 01:08 ET | 300 | 3.145 |
| 01:10 ET | 1500 | 3.135 |
| 01:14 ET | 8908 | 3.135 |
| 01:19 ET | 100 | 3.135 |
| 01:21 ET | 500 | 3.125 |
| 01:24 ET | 855 | 3.115 |
| 01:28 ET | 783 | 3.12 |
| 01:30 ET | 200 | 3.13 |
| 01:37 ET | 300 | 3.1309 |
| 01:39 ET | 1985 | 3.15 |
| 01:42 ET | 393 | 3.15 |
| 01:46 ET | 400 | 3.1532 |
| 01:53 ET | 1400 | 3.165 |
| 02:00 ET | 100 | 3.165 |
| 02:02 ET | 500 | 3.1509 |
| 02:04 ET | 200 | 3.155 |
| 02:06 ET | 300 | 3.1507 |
| 02:08 ET | 100 | 3.155 |
| 02:11 ET | 100 | 3.16 |
| 02:13 ET | 400 | 3.15 |
| 02:15 ET | 270 | 3.155 |
| 02:24 ET | 100 | 3.155 |
| 02:26 ET | 100 | 3.155 |
| 02:29 ET | 600 | 3.145 |
| 02:44 ET | 100 | 3.14 |
| 02:47 ET | 100 | 3.15 |
| 02:54 ET | 800 | 3.145 |
| 02:56 ET | 100 | 3.145 |
| 02:58 ET | 253 | 3.145 |
| 03:00 ET | 1000 | 3.1403 |
| 03:02 ET | 1320 | 3.1498 |
| 03:03 ET | 600 | 3.1443 |
| 03:09 ET | 200 | 3.145 |
| 03:12 ET | 100 | 3.145 |
| 03:14 ET | 200 | 3.145 |
| 03:16 ET | 600 | 3.145 |
| 03:18 ET | 600 | 3.145 |
| 03:21 ET | 876 | 3.145 |
| 03:23 ET | 2239 | 3.175 |
| 03:27 ET | 3864 | 3.2 |
| 03:30 ET | 7114 | 3.205 |
| 03:32 ET | 2504 | 3.21 |
| 03:34 ET | 209 | 3.21 |
| 03:36 ET | 5937 | 3.18 |
| 03:38 ET | 100 | 3.185 |
| 03:39 ET | 100 | 3.185 |
| 03:41 ET | 443 | 3.185 |
| 03:43 ET | 100 | 3.1825 |
| 03:45 ET | 400 | 3.185 |
| 03:48 ET | 180 | 3.185 |
| 03:52 ET | 1400 | 3.185 |
| 03:54 ET | 200 | 3.19 |
| 03:56 ET | 989 | 3.19 |
| 03:57 ET | 618 | 3.19 |
| 03:59 ET | 5878 | 3.19 |
Apr 16, 2024
Apr 4, 2024
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease, from 8:00AM ET on Thursday Apr 04, 2024 by Dow Jones
8:00AM ET on Thursday Apr 04, 2024 by Dow Jones
Mar 27, 2024
DJ Acumen Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co., from 9:30AM ET on Wednesday Mar 27, 2024 by Dow Jones
9:30AM ET on Wednesday Mar 27, 2024 by Dow Jones
Mar 26, 2024
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights, from 7:00AM ET on Tuesday Mar 26, 2024 by Dow Jones
7:00AM ET on Tuesday Mar 26, 2024 by Dow JonesPress Release: Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights, from 7:00AM ET on Tuesday Mar 26, 2024 by Dow Jones
7:00AM ET on Tuesday Mar 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Acumen Pharmaceuticals Inc | 191.1M | -2.9x | --- |
Elevation Oncology Inc | 188.8M | -2.4x | --- |
Atossa Therapeutics Inc | 188.0M | -6.4x | --- |
Cardiff Oncology Inc | 186.8M | -4.3x | --- |
Outlook Therapeutics Inc | 182.8M | -2.1x | --- |
Trevi Therapeutics Inc | 182.7M | -8.7x | --- |
Company Information
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in clinical development following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to Alzheimer’s pathology). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The Company is developing sabirnetug for intravenous (IV), administration every four weeks for the treatment of early AD.
Contact Information
- Headquarters
- 427 PARK ST.CHARLOTTESVILLE, VA, United States 22902
- Phone
- 925-368-8508
- Fax
- 302-636-5454
Executives
- President, Chief Development Officer
- James Doherty
- Chief Executive Officer, Director
- Daniel O'Connell
- Co-Founder, Chief Scientific Advisor
- Grant Krafft
- Chief Financial Officer, Chief Business Officer
- W. Matthew Zuga
- Chief Operating Officer
- Russell Barton
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $191.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 60.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.08 |
Book Value | $4.61 |
P/E Ratio | -2.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
